Lates News

After a sharp decline yesterday, today Hong Kong stocks in the innovative pharmaceutical concept sector rebounded across the board. As of the time of publication, Konruns Pharmaceuticals-B rose more than 14%, Huang Pharmaceutical rose more than 6%, Rundong Pharmaceuticals, Liputan Biological-B rose more than 5%, and Geco-B rose more than 4%. On the news front, many pharmaceutical companies responded, stating that they are aware of market rumors that the United States may limit innovative drugs from China, but believe that these rumors currently do not affect the expectations for Chinese innovative drugs to go global. Market participants believe that leading biotech companies such as BeiJing ShenZhou and Xinda Pharmaceuticals are expected to maintain a high growth trend after achieving a profit turning point in 2025. With the improvement of industrialization capabilities and expansion of product lines, it is expected that more biotech companies will enter the profit cycle in the future. (First Financial News)